RE:U.S.A, novel drugs, and NEW DRUG applications.
alleyesonme wrote: Have been submitted by pharmaceutical clients who've referenced the DMF held by MPL...this was mentioned in the MD&A and in the CC. Similar info is published on the investors deck found on the corporate website..I would image once rescheduling takes effect FDA approval is more easily attainable as opposed to the current schedule the API falls under... considering this information has been on the investor deck for well over a year the application has been sitting with the FDA for a LONG time....if approved this stock will explode and my view on the holdup has to do with the schedule and once this stance officially changes we could see approval shortly after..for this tight lipped management team to bring up the new drug applications for the first time on CC and MD&A is significant IMO
mad much as I believe in MPL I have to take a sober look at my investment ( having quite a chunk of change) tied up. I was hopeful to see a positive reaction after the Q1 numbers but for whatever reason MPL seems to not get any traction in a bull MJ market. For over a month and a half other MJ companies have rallied as far as SP is concerned, and even though MPL has put up excellent numbers and are one of the healthiest companies in this space we can't even get SP to break or even hit .10.
I will give this another quarter but if there is no significant change to SP (.15 +) I will reallocate my investment somewhere else.
there are many great opportunities in many sectors that are passing by.
this has nothing to do with MPL as a company it's just $ and Cents and if the $ invested don't make a reasonable return then they are not doing their job.
I hope MPL powers that be stop taking shareholders for granted and come up with a strategy to reward us by getting SP where it should be.